Artivion, Inc. (NYSE:AORT) Receives $51.00 Average Price Target from Brokerages
by Amy Steele · The Cerbat GemArtivion, Inc. (NYSE:AORT – Get Free Report) has been assigned an average rating of “Moderate Buy” from the eight ratings firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $51.00.
Several analysts recently issued reports on AORT shares. LADENBURG THALM/SH SH upgraded Artivion from a “neutral” rating to a “buy” rating and set a $42.00 price objective for the company in a report on Friday, April 10th. Wall Street Zen downgraded Artivion from a “buy” rating to a “hold” rating in a research note on Saturday. Needham & Company LLC reaffirmed a “buy” rating on shares of Artivion in a research report on Monday. Canaccord Genuity Group cut their price target on Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a research note on Friday, February 13th. Finally, Weiss Ratings upgraded Artivion from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, February 20th.
Check Out Our Latest Stock Analysis on Artivion
Insider Buying and Selling at Artivion
In other news, SVP Jean F. Holloway sold 8,962 shares of the stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $38.00, for a total transaction of $340,556.00. Following the transaction, the senior vice president owned 185,095 shares in the company, valued at $7,033,610. This represents a 4.62% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Lance A. Berry sold 6,316 shares of the firm’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $37.78, for a total transaction of $238,618.48. Following the transaction, the executive vice president owned 210,827 shares in the company, valued at $7,965,044.06. This represents a 2.91% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 133,043 shares of company stock worth $4,977,158 in the last ninety days. Insiders own 6.30% of the company’s stock.
Institutional Investors Weigh In On Artivion
Large investors have recently bought and sold shares of the business. Aster Capital Management DIFC Ltd raised its holdings in Artivion by 402.3% during the third quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock valued at $27,000 after buying an additional 519 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in shares of Artivion during the 3rd quarter worth about $27,000. Rockefeller Capital Management L.P. boosted its stake in shares of Artivion by 150.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock worth $30,000 after acquiring an additional 399 shares in the last quarter. Larson Financial Group LLC increased its holdings in shares of Artivion by 148.5% during the 4th quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock valued at $43,000 after acquiring an additional 563 shares during the last quarter. Finally, USA Financial Formulas increased its holdings in shares of Artivion by 163.5% during the 4th quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock valued at $52,000 after acquiring an additional 703 shares during the last quarter. 86.37% of the stock is currently owned by institutional investors.
Artivion Stock Performance
Shares of AORT opened at $37.74 on Wednesday. The company has a market capitalization of $1.83 billion, a PE ratio of 188.72 and a beta of 1.63. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.62 and a current ratio of 3.53. The company’s 50 day moving average price is $36.69 and its 200 day moving average price is $41.44. Artivion has a 52 week low of $23.04 and a 52 week high of $48.25.
Artivion (NYSE:AORT – Get Free Report) last released its earnings results on Thursday, February 12th. The company reported $0.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.03. Artivion had a net margin of 2.21% and a return on equity of 7.43%. The company had revenue of $118.30 million during the quarter, compared to the consensus estimate of $116.42 million. The company’s revenue was up 19.2% on a year-over-year basis. Research analysts expect that Artivion will post 0.63 EPS for the current fiscal year.
About Artivion
Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.
Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.